Lonza’s Synaffix Collaborates with Qurient Therapeutics on Dual-Payload ADC Development

Lonza’s Synaffix Collaborates with Qurient Therapeutics on Dual-Payload ADC Development

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), entered into a licensing agreement with Qurient, a clinical-stage biopharmaceutical company based in South Korea, for the development of a dual-payload ADC. Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct mechanisms of action to target cancer cells, aiming to enh…

Synaffix and Qurient enter licensing deal for dual-payload ADC

Synaffix has entered a licensing agreement with South Korean biopharmaceutical firm Qurient to develop a dual-payload ADC.

Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC - Optimum Strategic Communications

License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor Amsterdam, The Netherlands and Seongnam-Si, Korea, 25 September 2025 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic i…